Stereotaxis Inc is a medical device company that specializes in advanced robotic systems for the cardiovascular catheterization market. The company's innovative technologies focus on enhancing the precision and effectiveness of minimally invasive procedures, particularly in the treatment of arrhythmias and other heart conditions. By integrating advanced robotics and navigation systems, Stereotaxis aims to improve the outcomes of electrophysiological procedures, enabling physicians to perform complex interventions with greater safety and efficiency. Their commitment to innovation and patient care positions them as a leader in the evolving landscape of cardiac treatments. Read More
ST. LOUIS – April 6, 2026 – In a milestone that signals a paradigm shift for cardiac care, Stereotaxis (NYSE American: STXS) has received FDA 510(k) clearance for its Synchrony™ System. The approval marks the official commercial launch of the world’s first integrated "digital cockpit" for robotic electrophysiology (EP), a
ST. LOUIS — April 6, 2026 — Stereotaxis (NYSE: STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias and other endovascular procedures, announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Synchrony™ system. The clearance marks the final
iShares Biotechnology ETF (IBB) gives investors biotech exposure through large, established drug developers rather than smaller speculative names. That structure can offer more earnings visibility, but it also means giving up some upside when risk appetite shifts toward early-stage biotech companies.
